Douglas Eby is the Chief Executive Officer and Founder of Cambridge Science, a clinical stage biotechnology platform company, which is launching, financing and operating biotech companies commercializing biomedical technology developed at world leading medical research institutions.
He has served as the launch CEO of three Cambridge therapeutic companies. Douglas was a 2017 Harvard Fellow in the University’s Advanced Leadership Initiative and Senior Fellow at Harvard Law School, where he led the Innovative Funding Models for Translational Research Project at the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics. He is a past Fellow in the Harvard Law School Global Access in Action at the Berkman Klein Center for Internet & Society, where he was working on increasing access to medicines treating life threatening conditions and diseases in underserved countries. His work is focused on the improvement in global health through the acceleration of biomedical innovation.